UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 22, 2012
ASTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-27628 |
|
91-1841574 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
4140 Dublin Blvd., Suite 200
Dublin, CA 94568
(Address of principal executive offices, including zip code)
(925) 560-0100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders of Astex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) was held on June 22, 2012. The proposals submitted to a vote of the stockholders at the meeting are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2012. The final results of voting for each matter are as follows:
Proposal 1: Election of the Board of Directors of the Company.
|
Nominee |
|
Votes For |
|
Votes Withheld |
|
Broker |
|
|
|
|
|
|
|
|
|
|
|
Charles J. Casamento |
|
48,842,552 |
|
2,570,723 |
|
27,978,343 |
|
|
Peter Fellner |
|
46,581,175 |
|
4,832,100 |
|
27,978,343 |
|
|
Thomas V. Girardi |
|
47,253,044 |
|
4,160,231 |
|
27,978,343 |
|
|
Allan R. Goldberg |
|
49,172,563 |
|
2,240,712 |
|
27,978,343 |
|
|
Timothy Haines |
|
49,220,461 |
|
2,192,814 |
|
27,978,343 |
|
|
Harren Jhoti |
|
48,196,215 |
|
3,217,060 |
|
27,978,343 |
|
|
Ismail Kola |
|
47,429,512 |
|
3,983,763 |
|
27,978,343 |
|
|
Walter J. Lack |
|
45,121,623 |
|
6,291,652 |
|
27,978,343 |
|
|
James S.J. Manuso |
|
47,776,777 |
|
3,636,498 |
|
27,978,343 |
|
Proposal 2 Approval of amendments to the Company’s 2003 Stock Plan.
|
Votes For: |
|
41,402,030 |
|
|
Votes Against: |
|
9,826,201 |
|
|
Votes Abstaining: |
|
185,044 |
|
|
Broker Non-Votes: |
|
27,978,343 |
|
Proposal 3: Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2012.
|
Votes For: |
|
76,052,929 |
|
|
Votes Against: |
|
2,882,430 |
|
|
Votes Abstaining: |
|
456,259 |
|
Proposal 4: Non-binding advisory vote to approve executive compensation.
|
Votes For: |
|
45,125,083 |
|
|
Votes Against: |
|
5,017,267 |
|
|
Votes Abstaining: |
|
1,270,925 |
|
|
Broker Non-Votes: |
|
27,978,343 |
|
Each of Proposals 1 through 4 set forth above was approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ASTEX PHARMACEUTICALS, INC. |
|
|
|
|
|
|
By: |
/s/ MICHAEL MOLKENTIN |
|
|
|
Michael Molkentin |
|
|
|
Chief Financial Officer |
Date: June 25, 2012